Don’t miss these 2021 SABCS Special Sessions


Estimated Read Time:

2 minutes
Charles Perou, PhD
Charles Perou, PhD

Advances and updates in patient care with a special emphasis on equity and breast oncology in a post-COVID world will be the focus of four Special Sessions at the 44th annual San Antonio Breast Cancer Symposium.

On Tuesday, December 7, the Special Session Trust in Science and Healthcare will explore ways to build more trust in science and health care, particularly within communities of color.

This session will be co-hosted by Charles Perou, PhD, Professor of Genetics and Co-Director of the Lineberger Breast Cancer Research Program at the University of North Carolina-Chapel Hill, and Maimah Karmo, president and founder of the Tigerlily Foundation. Panelists will discuss the problem of health care inequity in breast cancer research and treatment and ways to maximize opportunities for synergistic collaborations with colleagues in cancer science and medicine.

The following Special Sessions will all be held on Wednesday, December 8.

Maimah Karmo
Maimah Karmo

Melissa Bondy, PhD, Professor of Epidemiology and Population Health at Stanford University, and Patty Spears, Research Patient Advocate, University of North Carolina at Chapel Hill, will co-moderate Health Equity in Translational Research Studies. This session will address disparities in translational research, including clinical trial accrual and biospecimen donation.

The Special Session Re-Framing Leadership in Academic Breast Oncology Post COVID-19 will be moderated by SABCS Co-Director Carlos Arteaga, MD, and Rebecca Dent, MD, MSc, of the National Cancer Centre Singapore. Topics covered in this session include learning by leading and building a successful translational breast program.

Laleh Amiri-Kordestani, MD, Director, CDER Division of Oncology 1 (DO1), at the Food and Drug Administration (FDA), will moderate the Special Session Regulatory Insights to the 2021 Early-Stage Breast Cancer Approvals. Panelists will discuss the status of new agents approved or pending approval for the treatment of early-stage breast cancer.

Check the 2021 SABCS program at for up-to-date session information.